Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA‐B Genotypes and Phenytoin Dosing: 2020 Update
Clinical Pharmacology & Therapeutics2020Vol. 109(2), pp. 302–309
Citations Over TimeTop 1% of 2020 papers
Jason H. Karnes, Allan E. Rettie, Andrew A. Somogyi, Rachel Huddart, Alison E. Fohner, Christine M. Formea, Ming Ta Michael Lee, Adrián LLerena, Michelle Whirl‐Carrillo, Teri E. Klein, Elizabeth J. Phillips, Scott Mintzer, Andrea Gaedigk, Kelly E. Caudle, John T. Callaghan
Abstract
Phenytoin is an antiepileptic drug with a narrow therapeutic index and large interpatient pharmacokinetic variability, partly due to genetic variation in CYP2C9. Furthermore, the variant allele HLA-B*15:02 is associated with an increased risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in response to phenytoin treatment. We summarize evidence from the published literature supporting these associations and provide therapeutic recommendations for the use of phenytoin based on CYP2C9 and/or HLA-B genotypes (updates on cpicpgx.org).
Related Papers
- → Toxic Epidermal Necrolysis Induced by Phenytoin and Whole Brain Radiotherapy(2007)14 cited
- → Phenytoin-induced toxic epidermal necrolysis: a case report(1996)11 cited
- → CYP2C9 polymorphisms are associated with phenytoin toxicity in South-Indian epileptic patients(2020)
- → Case Report on Phenytoin-Induced Toxic Epidermal Necrolysis(2022)